Trial Profile
A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Abatacept
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-CHOICE
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results reporting long-term safety and efficacy data of upadacitinib through week 204 presented at the ACR Convergence 2023
- 29 Jun 2023 This trial has been completed in Germany (Date of the global end of the trial: 06-Jun-2023), according to the European Clinical Trials Database record.
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.